Literature DB >> 17503141

Neuropsychological/-psychiatric deficits in immune-mediated neuropathies.

Andrew Chan1, Ralf Gold.   

Abstract

Albeit common, neuropsychological/psychiatric deficits in patients with autoimmune-mediated neuropathies have not received much attention; however, they can impose a considerable clinical problem. Especially in intensive-care treated Guillain Barré syndrome (GBS) severe psychosis may occur which may go unrecognised due to the severity of the neurological motor deficits. Fatigue may result in a major restriction of quality of life long after the acute phase of GBS and is also a major debilitating factor in chronic inflammatory neuropathies. Symptomatic treatment remains largely empirical.

Entities:  

Mesh:

Year:  2007        PMID: 17503141     DOI: 10.1007/s00415-007-2023-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

Review 1.  Neuromuscular disease causing acute respiratory failure.

Authors:  Sangeeta Mehta
Journal:  Respir Care       Date:  2006-09       Impact factor: 2.258

2.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

3.  Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome.

Authors:  V Cochen; I Arnulf; S Demeret; M L Neulat; V Gourlet; X Drouot; S Moutereau; J P Derenne; T Similowski; J C Willer; C Pierrot-Deseiligny; F Bolgert
Journal:  Brain       Date:  2005-07-06       Impact factor: 13.501

4.  [Oneiric perception in intensively treated panplegic polyradiculitis patients].

Authors:  M Schmidt-Degenhard
Journal:  Nervenarzt       Date:  1986-12       Impact factor: 1.214

5.  Long term disability and social status change after Guillain-Barré syndrome.

Authors:  A Bersano; M Carpo; S Allaria; D Franciotta; A Citterio; E Nobile-Orazio
Journal:  J Neurol       Date:  2005-08-17       Impact factor: 4.849

Review 6.  [An oneiroid experience during severe acute polyradiculoneuritis].

Authors:  K Wegener; P Tassan; M O Josse; F Bolgert
Journal:  Ann Med Psychol (Paris)       Date:  1995-02       Impact factor: 0.380

7.  Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; J P Samijn; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

8.  Central nervous system pathology in patients with the Guillain-Barré syndrome.

Authors:  H Maier; M Schmidbauer; B Pfausler; E Schmutzhard; H Budka
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

9.  Cytokine mRNA expression in patients with multiple sclerosis and fatigue.

Authors:  Peter Flachenecker; Irene Bihler; F Weber; M Gottschalk; Klaus V Toyka; Peter Rieckmann
Journal:  Mult Scler       Date:  2004-04       Impact factor: 6.312

10.  Resolution of chronic inflammatory demyelinating polyneuropathy-associated central nervous system lesions after treatment with intravenous immunoglobulin.

Authors:  Dominic B Fee; John O Fleming
Journal:  J Peripher Nerv Syst       Date:  2003-09       Impact factor: 3.494

View more
  3 in total

1.  Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis.

Authors:  Tiina Rekand; Arne Gramstad; Christian A Vedeler
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

2.  Inpatient Delirium in Guillain-Barré Syndrome: Frequency and Clinical Characteristics in a Mexican Hospital.

Authors:  Juan Carlos López-Hernández; Maria E Briseño-Godinez; Esther Y Pérez-Valdez; Raul N May-Mas; Javier A Galnares-Olalde; Victoria Martínez-Angeles; Jesus Ramírez-Bermudez; Elizabeth León-Manriquez; Gerardo Chavira-Hernández; Edwin Steven Vargas-Cañas
Journal:  Cureus       Date:  2021-11-04

Review 3.  Neuropsychiatric manifestations in inflammatory neuropathies: A systematic review.

Authors:  Yusuf A Rajabally; Stefano Seri; Andrea E Cavanna
Journal:  Muscle Nerve       Date:  2016-05-10       Impact factor: 3.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.